ENVALITH
森永乳業株式会社 logo

Morinaga Milk Industry Co., Ltd.

2264・Prime Market・Foods

Official website
森永乳業株式会社 logo
Morinaga Milk Industry Co., Ltd.2264

Business

The Morinaga Milk Industry Group is composed of the Company, 48 subsidiaries, and 4 affiliated companies, with food manufacturing and sales—centered on market milk, dairy products, ice cream, and beverages—as its core business. Domestically, the group supplies products to both BtoC and BtoB customers through its nationwide network of plants and sales subsidiaries, while overseas it pursues global expansion through subsidiaries such as MILEI GmbH (whey protein) in Germany, NutriCo Morinaga (infant formula) in Pakistan, and subsidiaries in Vietnam, the United States, and elsewhere. The group cultivates functional materials such as bifidobacteria and lactoferrin through proprietary research and development, building a multilayered business portfolio that combines BtoC branded products with BtoB material sales.

Business Model

In Japan, the company's foundation is high-volume revenue from the manufacturing and sale of market milk, yogurt, ice cream, cheese, beverages, and similar products, with profitability being enhanced through price revisions and product mix improvements. In parallel, this is combined with a high value-added business supplying functional materials such as bifidobacteria, lactoferrin, and lactulose to BtoB customers, together with an overseas whey protein and infant formula business centered on MILEI GmbH, forming a structure designed to diversify revenue and lift overall profit margins.

Company Strengths

Built on bifidobacteria research accumulated since the launch of Bifidus in 1977, the company holds multiple proprietary strains including BB536, MCC1274, and M-16V. In lactoferrin, it achieved acceptance of a Foods with Function Claims notification for "maintenance of immune function" (February 2025). With numerous awards at international academic conferences, the company has built up research assets that are difficult for competitors to replicate in the short term.

Domestically, the company operates major plants including Bekkai, Tone, Kobe, and Tokyo Tama, along with 16 sales subsidiaries including Morinaga Milk Industry Sales Co., Ltd., forming a nationwide production and distribution network. Overseas, it has consolidated subsidiaries in Germany, the United States, Pakistan, Vietnam, Singapore, and elsewhere, with the overseas sales ratio reaching 15.3% in FY2026 (ending March 2026).

MILEI GmbH of Germany, made a wholly owned subsidiary in 2012, pushed up overseas segment operating profit by ¥9,521 million year on year in FY2026 (ending March 2026), driven by elevated whey protein market prices and increased sales volume. Goodwill amortization expense also declined sharply, from ¥1,152 million in the prior period to ¥33 million in the current period, structurally expanding its profit contribution.

ENVALITH's Perspective

MILEI GmbH, which drove the significant profit increase in FY2026 (ending March 2026), included a temporary factor of increased sales volume from inventory, and FY2027 (ending March 2028) is expected to see a rebound decline in addition to cost increases such as higher raw material costs. As an external factor, a profit decline of ¥4.0 billion due to the impact of the Middle East situation has also been incorporated into the earnings forecast. Consolidated operating profit for FY2027 (ending March 2028) is forecast at ¥32,000 million (down 7.2% year-on-year), indicating a shift to profit decline, and verification of the sustainable growth capability of overseas operations will be the focus going forward.

In FY2026 (ending March 2026), cost increases continued, including raw milk trading price hikes, raw material costs, logistics costs, and labor costs, and although price revisions were implemented, the decline in sales volume exceeded initial assumptions. As an external factor, the demand environment for food products in general is severe, and consumer price sensitivity is increasing. With similar cost increases expected to continue in FY2027 (ending March 2028), achieving both improved product mix and volume recovery is essential for improving domestic business profitability, and whether the improvement in yogurt sales continues will be a point of focus.

In FY2025 (ending March 2025), net income plunged to ¥5,459 million due to the recording of an impairment loss of ¥20,483 million, but in FY2026 (ending March 2026), the impairment loss shrank to ¥3,553 million, and net income recovered significantly to ¥22,599 million (up 313.9% year-on-year). The volatility in extraordinary gains and losses has narrowed, and the structure is improving such that operating profit-based earning power is more readily reflected in net income. However, the forecast for net income in FY2027 (ending March 2028) is ¥20,000 million (down 11.5% year-on-year), indicating an expected decline in profit, and maintaining profit levels to achieve the medium-term target of ROE of 10% remains a challenge.

Growth Strategy

Through concentration of resources on the four growth areas and structural reform, the company aims to achieve an operating margin of 7% and ROE of 10% by FY2029 (ending March 2029).

In FY2026 (ending March 2026), all four growth-area categories achieved sales growth (net sales of ¥124,529 million, up 5.2% year on year). For FY2027 (ending March 2027), growth-area net sales of ¥135,800 million (up 9.1%) and operating profit of ¥13,900 million (up ¥1,309 million year on year) are projected, with continued efforts to expand high-value-added products.

New ice cream manufacturing facilities began operation in FY2026 (ending March 2026), addressing lost sales opportunities and responding to increased sales volume. Capital expenditures expanded to ¥39,999 million in fixed asset acquisitions, up from ¥32,224 million the previous year. In the first year of operation, increased depreciation expenses weighed on growth-area operating profit, but medium- to long-term earnings contribution is expected.

Overseas business net sales in FY2026 (ending March 2026) expanded significantly to ¥87,474 million (up 25.1% year on year), with operating profit of ¥16,997 million (up ¥9,521 million year on year). The overseas sales ratio of 15.3% has already achieved the medium-term target of 15%. For FY2027 (ending March 2027), overseas business operating profit is projected at ¥16,000 million (down ¥998 million year on year) due to a rebound decline at MILEI, but continued growth in functional bacterial strains and infant formula is expected to offset this.

In FY2026 (ending March 2026), the company conducted approximately ¥10 billion in share buybacks and cancellations, raising its dividend payout ratio target to 40%. ROE improved substantially from 2.0% (FY2025, ending March 2025) to 8.4% (FY2026, ending March 2026). A four-for-one stock split was implemented effective July 1, 2026, aimed at broadening the investor base. For FY2027 (ending March 2027), the annual dividend is planned at ¥25 post-split (equivalent to ¥100 pre-split), with a dividend payout ratio of 40.3%.

The company has decided on a basic policy to absorb its wholly owned subsidiary Morinaga Milk Sales Co., Ltd. through a merger, planned for April 2027. The objectives are to consolidate management resources, strengthen and streamline sales activities, increase speed, and reinforce group governance. Preparations such as system integration and customer contract procedures are underway, with the merger agreement scheduled to be concluded in March 2027. The impact on consolidated results is expected to be minor.

Last updated: July 19, 2026